Novel compounds targeting InhA for TB therapy

被引：21

作者：

AlMatara, Manaf ^{[1
]}

Makky, Essam A. ^{[2
]}

Var, Isil ^{[3
]}

Kayar, Begum ^{[4
]}

Koksal, Fatih ^{[4
]}

机构：

[1] Cukurova Univ, Dept Biotechnol, Inst Nat & Appl Sci Fen Bilimleri Enstitusu, Adana, Turkey

[2] Univ Malaysia Pahang UMP, Fac Ind Sci & Technol, Dept Biotechnol, Kuantan, Malaysia

[3] Cukurova Univ, Fac Agr, Dept Food Engn, Adana, Turkey

[4] Cukurova Univ, Fac Med, Dept Med Microbiol, Adana, Turkey

来源：

PHARMACOLOGICAL REPORTS | 2018年 / 70卷 / 02期

关键词：

Tuberculosis; Isoniazid resistance; Enoyl ACP reductase; InhA inhibitor; Novel drugs; CARRIER PROTEIN REDUCTASE; KILL MYCOBACTERIUM-TUBERCULOSIS; MATCHED MOLECULAR PAIRS; GALLIC ACID-DERIVATIVES; ENOYL-ACP REDUCTASE; DRUG-RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ISONIAZID-RESISTANT; ANTIMYCOBACTERIAL ACTIVITY; ANTIMICROBIAL RESISTANCE;

D O I：

10.1016/j.pharep.2017.09.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tuberculosis (TB) is described as lethal disease in the world. Resistant to TB drugs is the main reason to have unfavourable outcomes in the treatment of TB. Therefore, new agents to replace existing drugs are urgently needed. Previous reports suggested that InhA inhibitors, an enoyl-ACP-reductase, might provide auspicious candidates which can be developed into novel antitubercular agents. In this review, we explain the role of InhA in the resistance of isoniazid. Furthermore, five classes of InhA inhibitors, which display novel binding modes and deliver evidence of their prosperous target engagement, have been debated. (C) 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o. o. All rights reserved.

引用

页码：217 / 226

页数：10